<![CDATA[Botensilimab/Balstilimab Elicits Major Pathologic Responses in Colon Cancer]]>

Phase 2positiveBotensilimabBalstilimabPositive

AI Analysis

Summary

Botensilimab plus balstilimab demonstrated major pathologic responses in 41% of pMMR and 100% of dMMR colorectal tumors in the phase 2 NEST trial. The combination showed promising neoadjuvant activity, particularly in mismatch repair-deficient tumors.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Major pathologic responses in 41% of pMMR and 100% of dMMR colorectal tumors

Importance:7/10

Sentiment:

0.80

neoadjuvantcolorectal cancerimmunotherapypathologic responsemMMRdMMR

Read the original article

Published by Cancer Network on August 28, 2026 2:00 PM

Read Original